GO:0008174 mRNA methyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008174 (mRNA methyltransferase activity) describes the catalysis of methyl-group transfer from S-adenosyl-L-methionine to a nucleoside residue within an mRNA molecule.
• The best-characterized mRNA methyltransferase is METTL3, the catalytic subunit of the m6A writer complex, which deposits N6-methyladenosine (m6A) on mRNA.
• Additional mRNA methyltransferases include METTL16, which can act m6A-independently to facilitate translation and tumorigenesis, and TRMT61B, which methylates mRNA and influences translation.
• m6A mRNA methylation regulates transcript stability, translation, chromatin state, and immune signaling, with roles in neuroinflammation, neutrophil activation, and cancer.
• Dysregulated mRNA methyltransferase activity is implicated in esophageal squamous cell carcinoma, neuroinflammatory disease, and tumorigenesis.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential for dissecting the causal roles of mRNA methyltransferase genes in disease.
Description
GO:0008174, mRNA methyltransferase activity, is a molecular function term describing the catalysis of methyl-group transfer from S-adenosyl-L-methionine (SAM) to a nucleoside residue in an mRNA molecule. This activity is central to epitranscriptomic regulation, where covalent RNA modifications such as N6-methyladenosine (m6A) and 5-methylcytosine (m5C) expand the informational capacity of mRNA and influence nearly every step of the mRNA life cycle. The m6A modification, installed by the METTL3-METTL14 writer complex, is the most abundant internal mRNA methylation and serves as a dynamic mark recognized by reader proteins that dictate transcript fate. Beyond m6A, additional methyltransferases such as METTL16 and TRMT61B contribute to mRNA methylation with distinct substrate specificities and biological outcomes. Because mRNA methyltransferase activity directly shapes gene expression programs, researchers across cancer biology, immunology, and neuroscience study this GO term to understand disease mechanisms and identify therapeutic targets.
mRNA methyltransferase activity At A Glance
| GO ID | GO:0008174 |
|---|---|
| GO term | mRNA methyltransferase activity |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Catalysis of the transfer of a methyl group from S-adenosyl-L-methionine to a nucleoside residue in an mRNA molecule. |
| Major function | Deposition of methyl marks such as m6A and m5C on mRNA transcripts. |
| Cofactor | S-adenosyl-L-methionine (SAM) serves as the methyl donor. |
| Representative enzymes | METTL3, METTL14, METTL16, TRMT61B, and other mRNA methyltransferases. |
| Biological impact | Regulates mRNA stability, translation, chromatin state, and immune signaling. |
What Is GO:0008174?
In our own words, GO:0008174 (mRNA methyltransferase activity) is the enzymatic function by which a methyl group is transferred from the cofactor S-adenosyl-L-methionine to a nucleoside residue within an mRNA molecule. This definition encompasses the catalytic step itself, regardless of whether the methylated nucleoside is adenosine (yielding m6A), cytosine (yielding m5C), or another modified base, and it applies to any enzyme that uses mRNA as a methyl-accepting substrate.
Why Is mRNA methyltransferase activity Important in Cell Biology?
mRNA methyltransferase activity is important because it installs reversible chemical marks that control how mRNA transcripts are processed, translated, and degraded, thereby shaping gene expression programs in development, immunity, and disease. The m6A mark deposited by METTL3-containing complexes influences transcript fate and has been linked to cancer progression, neuroinflammation, and neutrophil activation. METTL16 can promote translation and tumorigenesis through m6A-independent mechanisms, illustrating that mRNA methyltransferase activity extends beyond m6A catalysis. Additionally, m6A on chromosome-associated regulatory RNA regulates chromatin state and transcription, connecting mRNA methylation to nuclear gene regulation. Consequently, understanding GO:0008174 is essential for researchers investigating epitranscriptomic control of health and disease.
• Controls mRNA stability and translation through reversible methylation marks.
• Regulates chromatin state and transcription via m6A on chromosome-associated regulatory RNA.
• Drives tumorigenesis and cancer progression, including esophageal squamous cell carcinoma.
• Modulates neuroinflammation and neurotoxicity in microglia.
• Regulates neutrophil activation through TLR4 signaling.
• Provides a druggable node for epitranscriptomic therapeutics.
• Enables m6A-independent functions such as translation facilitation by METTL16.
• Serves as a biomarker and mechanistic target across multiple cancer types.
• Influences immune cell signaling and inflammatory responses.
• Requires precise CRISPR models to distinguish catalytic from non-catalytic functions.
What Happens During mRNA methyltransferase activity?
Substrate recognition and binding
In simple terms: The enzyme first finds and grabs the mRNA it will modify.
mRNA methyltransferases recognize specific sequence or structural features within target transcripts to achieve substrate specificity. The METTL3-METTL14 complex, for example, binds mRNA and positions the target adenosine for methylation, with METTL3 serving as the catalytic subunit and METTL14 contributing to RNA binding and complex stability. This recognition step ensures that methylation is deposited at defined sites rather than randomly across the transcriptome.
Methyl-group transfer from SAM
In simple terms: The enzyme takes a methyl group from a donor molecule and attaches it to the mRNA base.
Once the mRNA substrate is bound, the enzyme catalyzes transfer of a methyl group from S-adenosyl-L-methionine to a nucleoside residue in the mRNA. For m6A, this yields N6-methyladenosine on the target adenosine. The reaction is the defining catalytic event of GO:0008174 and is shared across mRNA methyltransferases that use SAM as the methyl donor.
Formation of the m6A mark and reader recruitment
In simple terms: The new methyl mark acts like a flag that other proteins can read.
After deposition, the m6A mark is recognized by reader proteins that interpret the modification and dictate downstream outcomes such as transcript stabilization, degradation, or enhanced translation. This reader-mediated interpretation converts the chemical mark into biological function, linking mRNA methyltransferase activity to changes in gene expression.
m6A-independent and non-canonical activities
In simple terms: Some methyltransferases do important jobs that do not require making the m6A mark.
METTL16 can exert an m6A-independent function to facilitate translation and tumorigenesis, demonstrating that mRNA methyltransferase proteins may have activities beyond canonical m6A catalysis. TRMT61B has also been investigated for methyltransferase activity on mRNA and its effects on translation. These findings broaden the functional scope of GO:0008174 and highlight the need to separate catalytic from non-catalytic roles experimentally.
Regulation of mRNA methylation dynamics
In simple terms: The amount and location of mRNA methylation can go up or down depending on cellular signals.
m6A RNA methylation is dynamically regulated and has therapeutic potential, meaning the activity of writer complexes can be modulated in response to cellular context. Chromosome-associated regulatory RNA methylation further shows that m6A can regulate chromatin state and transcription, integrating mRNA methyltransferase activity with nuclear regulatory networks. This dynamic regulation allows cells to tune gene expression programs through controlled methyl-group deposition.
Key Genes Involved in GO:0008174 mRNA methyltransferase activity
The following genes and proteins represent the major enzymatic and regulatory components associated with mRNA methyltransferase activity (GO:0008174).
| Gene | Major Role | Research Relevance |
|---|---|---|
| METTL3 | Catalytic subunit of the m6A writer complex that deposits m6A on mRNA | Central to m6A biology; drives neuroinflammation and neutrophil activation |
| METTL14 | RNA-binding subunit that supports METTL3 catalytic activity | Required for efficient m6A deposition and complex stability |
| METTL16 | m6A-independent facilitator of translation and tumorigenesis | Links mRNA methyltransferase proteins to cancer and translation control |
| TRMT61B | mRNA methyltransferase affecting translation | Expands the repertoire of mRNA-modifying enzymes |
| WTAP | Regulatory component of the m6A methyltransferase complex | Modulates complex assembly and substrate targeting |
| VIRMA | Component associated with m6A writer complex function | Contributes to methylation site selection and regulation |
| RBM15 | RNA-binding factor implicated in m6A complex targeting | Helps recruit the writer complex to specific transcripts |
| ZC3H13 | Accessory factor in the m6A methyltransferase complex | Supports complex integrity and methylation activity |
| YBX1 | m5C reader that stabilizes target mRNA | Links mRNA methylation readers to cancer progression |
| SMOX | m5C-regulated transcript stabilized via YBX1 | Model for m5C-dependent mRNA stabilization in cancer |
| BATF | m6A-stabilized mRNA in microglia | Connects METTL3 activity to neuroinflammation |
| TLR4 | m6A-regulated signaling component in neutrophils | Links mRNA methylation to innate immune activation |
| FTO | m6A demethylase that reverses the mark | Counterbalances mRNA methyltransferase activity |
| ALKBH5 | m6A demethylase involved in mark removal | Provides dynamic control of m6A levels |
| YTHDF proteins | m6A reader family that interprets the mark | Mediates downstream effects on mRNA fate |
| IGF2BP proteins | m6A reader family that stabilizes transcripts | Contributes to methylation-dependent mRNA stabilization |
| HNRNP proteins | RNA-binding readers of m6A | Participate in methylation-dependent processing |
How Is mRNA methyltransferase activity Regulated?
mRNA methyltransferase activity is dynamically regulated, and m6A RNA methylation has been reviewed as a process with therapeutic potential, indicating that its levels and effects can be modulated in cells. The activity and specificity of the mRNA m6A methyltransferase complex are governed by its subunit composition and RNA-binding accessory factors, which determine where methylation is deposited. In addition, demethylases such as FTO and ALKBH5 reverse the mark, providing a counterbalancing layer of regulation. Chromosome-associated regulatory RNA methylation further shows that m6A can regulate chromatin state and transcription, linking mRNA methyltransferase activity to nuclear regulatory programs.
mRNA methyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| METTL3 | Neuroinflammation and neurotoxicity via BATF mRNA stabilization | Microglial knockout and overexpression models |
| METTL3 | Neutrophil activation through TLR4 signaling | Neutrophil-specific knockout models |
| METTL16 | Tumorigenesis via m6A-independent translation facilitation | Cancer cell line knockout and rescue models |
| YBX1 | Esophageal squamous cell carcinoma progression via m5C-dependent SMOX stabilization | Knockdown and overexpression in ESCC models |
| m6A regulatory RNA | Chromatin state and transcription regulation | Chromatin-associated RNA perturbation models |
Cancer and tumorigenesis
mRNA methyltransferase activity is linked to cancer through multiple mechanisms. METTL16 exerts an m6A-independent function to facilitate translation and tumorigenesis, showing that mRNA methyltransferase proteins can promote cancer independently of canonical m6A catalysis. In esophageal squamous cell carcinoma, YBX1 promotes progression via m5C-dependent SMOX mRNA stabilization, illustrating how mRNA methylation readers and modified transcripts drive tumor biology. These findings position mRNA methyltransferase activity and its associated factors as potential therapeutic targets in oncology.
Neuroinflammation and neurotoxicity
The m6A methyltransferase METTL3 drives neuroinflammation and neurotoxicity through stabilizing BATF mRNA in microglia, directly connecting mRNA methyltransferase activity to inflammatory signaling in the central nervous system. This work suggests that modulating METTL3 activity or its target transcripts could influence neuroinflammatory disease processes.
Immune regulation and neutrophil activation
METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling, demonstrating a role for mRNA methyltransferase activity in innate immune cell function. This link between m6A deposition and TLR4 signaling highlights how epitranscriptomic marks shape immune responses and inflammatory pathways.
Chromatin regulation and transcriptional control
m6A on chromosome-associated regulatory RNA regulates chromatin state and transcription, expanding the disease relevance of mRNA methyltransferase activity to nuclear gene regulation. Dysregulation of this axis could contribute to diseases characterized by aberrant chromatin and transcriptional programs.
From mRNA methyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is the catalytic activity of an mRNA methyltransferase required for a phenotype? | Point-mutation knock-in of catalytic-dead residues |
| Does loss of an mRNA methyltransferase gene affect transcript stability or translation? | CRISPR knockout cell lines followed by RNA-seq and Ribo-seq |
| Can a disease-associated mutation in an mRNA methyltransferase alter substrate specificity? | Knock-in of the patient mutation and methylation profiling |
| Where and when is an mRNA methyltransferase expressed? | Tagged knock-in with fluorescent or affinity tags |
| Does overexpression of an mRNA methyltransferase drive transformation? | Stable overexpression in cancer cell lines |
| Which transcripts are directly methylated by a given enzyme? | Catalytically active versus inactive knock-in with m6A mapping |
How to Study the mRNA methyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| m6A mapping | Location of m6A marks on mRNA | Determining substrate specificity of methyltransferases |
| RNA-seq | Changes in transcript abundance | Identifying methylation-dependent mRNA stability |
| Ribo-seq | Translational efficiency of transcripts | Testing effects of methyltransferases on translation |
| CRISPR knockout | Loss-of-function phenotype | Testing requirement for a methyltransferase gene |
| Point-mutation knock-in | Catalytic versus non-catalytic function | Separating enzymatic from scaffolding roles |
| Tagged knock-in | Protein localization and interactions | Tracking methyltransferase complex components |
| Overexpression | Gain-of-function effects | Modeling oncogenic roles of methyltransferases |
m6A mapping and methylation profiling
Mapping m6A sites across the transcriptome is essential to determine where mRNA methyltransferase activity deposits marks. These approaches reveal substrate specificity and help distinguish direct from indirect effects of enzyme perturbation.
RNA-seq and transcript stability analysis
RNA sequencing after knockout or knockdown of an mRNA methyltransferase can identify transcripts whose stability depends on methylation. Such experiments link methylation status to changes in steady-state mRNA levels.
Translation profiling
Translation-focused assays are used to determine whether mRNA methyltransferase activity affects protein synthesis, as shown for METTL16 and TRMT61B. These methods connect methylation to translational output.
CRISPR-based perturbation and rescue
CRISPR knockout, point mutation, and rescue experiments are used to test whether catalytic activity or non-catalytic functions of an mRNA methyltransferase are responsible for a phenotype. This strategy is critical for separating m6A-dependent from m6A-independent roles.
How CRISPR Can Be Used to Study GO:0008174 mRNA methyltransferase activity
Knockout
CRISPR knockout of mRNA methyltransferase genes such as METTL3 or METTL16 allows researchers to test whether the enzyme is required for a given phenotype, including effects on mRNA stability, translation, and disease progression. Knockout models are foundational for linking GO:0008174 to biological outcomes.
Point Mutation
Point-mutation knock-in of catalytic residues can abolish methyltransferase activity while preserving protein expression, enabling separation of catalytic from non-catalytic functions. This is particularly important for enzymes like METTL16 that have m6A-independent roles.
Knock-in
Knock-in of tags, reporters, or disease-associated mutations allows precise tracking of mRNA methyltransferase localization, complex assembly, and substrate interactions. Such models help define how mutations alter methylation specificity and downstream signaling.
Overexpression
Overexpression of mRNA methyltransferases can model gain-of-function states observed in cancer and inflammatory disease, revealing how excess methylation activity alters transcript fate and cellular behavior. These models complement loss-of-function studies to establish causality.
How EDITGENE Supports mRNA methyltransferase activity Research
Researchers studying mRNA methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a disease phenotype, whether its catalytic activity is required, and which transcripts it directly methylates. Addressing these questions requires precise, reproducible cell models that can isolate enzymatic function from scaffolding or non-catalytic roles.
Contact EDITGENE today to design your custom CRISPR model for mRNA methyltransferase activity research.
Frequently Asked Questions About mRNA methyltransferase activity
What is mRNA methyltransferase activity?
mRNA methyltransferase activity (GO:0008174) is the catalysis of methyl-group transfer from S-adenosyl-L-methionine to a nucleoside residue in an mRNA molecule.
What genes are involved in mRNA methyltransferase activity?
Key genes include METTL3, METTL14, METTL16, and TRMT61B, along with complex components such as WTAP and VIRMA.
What is the GO ID for mRNA methyltransferase activity?
The GO ID is GO:0008174, classified under the molecular_function ontology.
How does m6A methylation affect mRNA?
m6A methylation can alter mRNA stability, translation, and reader-protein recruitment, thereby shaping gene expression.
Is METTL16 an m6A methyltransferase?
METTL16 can exert an m6A-independent function to facilitate translation and tumorigenesis, showing it has roles beyond canonical m6A catalysis.
What diseases are linked to mRNA methyltransferase activity?
It has been linked to cancer, neuroinflammation, neutrophil activation, and chromatin dysregulation.
How do you study mRNA methyltransferase activity?
Common approaches include m6A mapping, RNA-seq, Ribo-seq, and CRISPR knockout or point-mutation models.
What is the role of METTL3 in neuroinflammation?
METTL3 drives neuroinflammation and neurotoxicity by stabilizing BATF mRNA in microglia.
Does mRNA methylation regulate immune signaling?
Yes, METTL3-mediated m6A methylation regulates neutrophil activation through TLR4 signaling.
Can CRISPR be used to study mRNA methyltransferase function?
Yes, CRISPR knockout, point-mutation knock-in, and overexpression models are used to dissect catalytic and non-catalytic functions.
Conclusion
GO:0008174 (mRNA methyltransferase activity) defines the enzymatic deposition of methyl marks such as m6A on mRNA, a process that controls transcript fate and gene expression programs. Its dysregulation is implicated in cancer, neuroinflammation, immune signaling, and chromatin regulation, making it a high-value target for mechanistic and therapeutic research. Precise CRISPR models and epitranscriptomic profiling are essential to determine which functions of mRNA methyltransferases are causal in disease.
References
- 1. He PC et al.. 2021. m(6) A RNA methylation: from mechanisms to therapeutic potential.. EMBO J 40(3):e105977 PMID: 33470439
- 2. Garcias Morales D et al.. 2021. A birds'-eye view of the activity and specificity of the mRNA m(6) A methyltransferase complex.. Wiley Interdiscip Rev RNA 12(1):e1618 PMID: 32686365
- 3. Liu L et al.. 2024. YBX1 Promotes Esophageal Squamous Cell Carcinoma Progression via m5C‐Dependent SMOX mRNA Stabilization.. Adv Sci (Weinh) 11(20):e2302379 PMID: 38566431
- 4. Liu J et al.. 2020. N (6)-methyladenosine of chromosome-associated regulatory RNA regulates chromatin state and transcription.. Science 367(6477):580-586 PMID: 31949099
- 5. Fang D et al.. 2026. Investigation of TRMT61B methyltransferase activity on mRNA and its effects on translation.. Nucleic Acids Res 54(8) PMID: 42059200
- 6. Su R et al.. 2022. METTL16 exerts an m(6)A-independent function to facilitate translation and tumorigenesis.. Nat Cell Biol 24(2):205-216 PMID: 35145225
- 7. Wu X et al.. 2025. The m(6)A methyltransferase METTL3 drives neuroinflammation and neurotoxicity through stabilizing BATF mRNA in microglia.. Cell Death Differ 32(1):100-117 PMID: 38902548
- 8. Luo S et al.. 2023. METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling.. Cell Rep 42(3):112259 PMID: 36920907
